CTRI/2024/02/062382尚未招募2 期
Phase II trial of safety and efficacy after thrice weekly Osimertinib combined with standard of care chemotherapy in patients with Epidermal Growth Factor Receptor (EGFR) Positive advanced Non-small cell lung carcinoma (NSCLC)
Ashish Singh0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Metastatic non small cell carcinoma
- •2) EGFR mutation positive lung cancer
- •3) Performance status 0-1
排除标准
- •1) Previously treated lung cancer
- •2) Unstable CNS metastasis
- •3) Concurrent other malignancies
- •4) Major cardiac condition
- •5) Inadequate bone marrow reserve
- •6) Pregnancy
研究者
相似试验
招募中
1 期
Clinical study to assess the efficacy and safety of sublingual allergen immunotherapy spray in patients suffering from house dust mite allergyPatients with house dust mites related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthmaMedDRA version: 21.1Level: PTClassification code 10039085Term: Rhinitis allergicSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: PTClassification code 10010744Term: Conjunctivitis allergicSystem Organ Class: 10015919 - Eye disordersMedDRA version: 21.1Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-005169-41-DEROXALL Medizin GmbH996
进行中（未招募）
1 期
Phase II-III study to assess the efficacy and safety ofsublingual immunotherapy in patients suffering from grasspollen allergyModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollenfor at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA)guidelineCTIS2023-505880-35-00ROXALL Medizin GmbH512
进行中（未招募）
不适用
A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects. - NDsubjects suffering from house dust mite allergyMedDRA version: 8.1Level: LLTClassification code 10057631Term: House dust allergyEUCTR2006-001795-20-ITALK-ABELLO800
进行中（未招募）
1 期
A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects - ALK House Dust Mite TabletIgE mediated House dust mite induced mild to moderate asthma and mild to severe allergic rhinitis.EUCTR2006-001795-20-GBALK-Abelló A/S604
进行中（未招募）
不适用
A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjectsIgE mediated House dust mite induced mild to moderate asthma and mild to severe allergic rhinitis.EUCTR2006-001795-20-DKALK-Abelló A/S800